Dysfunctional endothelial progenitor cells in metabolic syndrome

Sridevi Devaraj, Ishwarlal Jialal

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The metabolic syndrome (MetS) is highly prevalent and confers an increased risk of diabetes and cardiovascular disease. A key early event in atherosclerosis is endothelial dysfunction. Numerous groups have reported endothelial dysfunction in MetS. However, the measurement of endothelial function is far from optimum. There has been much interest recently in a subtype of progenitor cells, termed endothelial progenitor cells (EPCs), that can circulate, proliferate, and dfferentiate into mature endothelial cells. EPCs can be characterized by the assessment of surface markers, CD34 and vascular endothelial growth factor receptor-2, VEGFR-2 (KDR). The CD34 +KDR+ phenotype has been demonstrated to be an independent predictor of cardiovascular outcomes. MetS patients without diabetes or cardiovascular diseases have decreased EPC number and functionality as evidenced by decreased numbers of colony forming units, decreased adhesion and migration, and decreased tubule formation. Strategies that have been shown to upregulate and enhance EPC number and functionality include statins, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and peroxisome-proliferator- activating-receptor gamma agonists. Mechanisms by which they affect EPC number and functionality need to be studied. Thus, EPC number and/or functionality could emerge as novel cellular biomarkers of endothelial dysfunction and cardiovascular disease risk in MetS.

Original languageEnglish (US)
Article number585018
JournalExperimental Diabetes Research
Volume2012
DOIs
StatePublished - 2012

Fingerprint

Cell Count
Vascular Endothelial Growth Factor Receptor-2
Cardiovascular Diseases
Stem Cells
Peroxisome Proliferators
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Endothelial Progenitor Cells
Syndrome
Cells
Atherosclerosis
Up-Regulation
Endothelial Cells
Biomarkers
Phenotype
Functionality
Cardiovascular Disease
Diabetes

ASJC Scopus subject areas

  • Medicine(all)
  • Endocrinology, Diabetes and Metabolism
  • Music

Cite this

Dysfunctional endothelial progenitor cells in metabolic syndrome. / Devaraj, Sridevi; Jialal, Ishwarlal.

In: Experimental Diabetes Research, Vol. 2012, 585018, 2012.

Research output: Contribution to journalArticle

Devaraj, Sridevi ; Jialal, Ishwarlal. / Dysfunctional endothelial progenitor cells in metabolic syndrome. In: Experimental Diabetes Research. 2012 ; Vol. 2012.
@article{86cc1852436143158eb86e60687b978e,
title = "Dysfunctional endothelial progenitor cells in metabolic syndrome",
abstract = "The metabolic syndrome (MetS) is highly prevalent and confers an increased risk of diabetes and cardiovascular disease. A key early event in atherosclerosis is endothelial dysfunction. Numerous groups have reported endothelial dysfunction in MetS. However, the measurement of endothelial function is far from optimum. There has been much interest recently in a subtype of progenitor cells, termed endothelial progenitor cells (EPCs), that can circulate, proliferate, and dfferentiate into mature endothelial cells. EPCs can be characterized by the assessment of surface markers, CD34 and vascular endothelial growth factor receptor-2, VEGFR-2 (KDR). The CD34 +KDR+ phenotype has been demonstrated to be an independent predictor of cardiovascular outcomes. MetS patients without diabetes or cardiovascular diseases have decreased EPC number and functionality as evidenced by decreased numbers of colony forming units, decreased adhesion and migration, and decreased tubule formation. Strategies that have been shown to upregulate and enhance EPC number and functionality include statins, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and peroxisome-proliferator- activating-receptor gamma agonists. Mechanisms by which they affect EPC number and functionality need to be studied. Thus, EPC number and/or functionality could emerge as novel cellular biomarkers of endothelial dysfunction and cardiovascular disease risk in MetS.",
author = "Sridevi Devaraj and Ishwarlal Jialal",
year = "2012",
doi = "10.1155/2012/585018",
language = "English (US)",
volume = "2012",
journal = "Experimental Diabetes Research",
issn = "1687-5214",
publisher = "Taylor and Francis Ltd.",

}

TY - JOUR

T1 - Dysfunctional endothelial progenitor cells in metabolic syndrome

AU - Devaraj, Sridevi

AU - Jialal, Ishwarlal

PY - 2012

Y1 - 2012

N2 - The metabolic syndrome (MetS) is highly prevalent and confers an increased risk of diabetes and cardiovascular disease. A key early event in atherosclerosis is endothelial dysfunction. Numerous groups have reported endothelial dysfunction in MetS. However, the measurement of endothelial function is far from optimum. There has been much interest recently in a subtype of progenitor cells, termed endothelial progenitor cells (EPCs), that can circulate, proliferate, and dfferentiate into mature endothelial cells. EPCs can be characterized by the assessment of surface markers, CD34 and vascular endothelial growth factor receptor-2, VEGFR-2 (KDR). The CD34 +KDR+ phenotype has been demonstrated to be an independent predictor of cardiovascular outcomes. MetS patients without diabetes or cardiovascular diseases have decreased EPC number and functionality as evidenced by decreased numbers of colony forming units, decreased adhesion and migration, and decreased tubule formation. Strategies that have been shown to upregulate and enhance EPC number and functionality include statins, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and peroxisome-proliferator- activating-receptor gamma agonists. Mechanisms by which they affect EPC number and functionality need to be studied. Thus, EPC number and/or functionality could emerge as novel cellular biomarkers of endothelial dysfunction and cardiovascular disease risk in MetS.

AB - The metabolic syndrome (MetS) is highly prevalent and confers an increased risk of diabetes and cardiovascular disease. A key early event in atherosclerosis is endothelial dysfunction. Numerous groups have reported endothelial dysfunction in MetS. However, the measurement of endothelial function is far from optimum. There has been much interest recently in a subtype of progenitor cells, termed endothelial progenitor cells (EPCs), that can circulate, proliferate, and dfferentiate into mature endothelial cells. EPCs can be characterized by the assessment of surface markers, CD34 and vascular endothelial growth factor receptor-2, VEGFR-2 (KDR). The CD34 +KDR+ phenotype has been demonstrated to be an independent predictor of cardiovascular outcomes. MetS patients without diabetes or cardiovascular diseases have decreased EPC number and functionality as evidenced by decreased numbers of colony forming units, decreased adhesion and migration, and decreased tubule formation. Strategies that have been shown to upregulate and enhance EPC number and functionality include statins, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and peroxisome-proliferator- activating-receptor gamma agonists. Mechanisms by which they affect EPC number and functionality need to be studied. Thus, EPC number and/or functionality could emerge as novel cellular biomarkers of endothelial dysfunction and cardiovascular disease risk in MetS.

UR - http://www.scopus.com/inward/record.url?scp=81555201107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81555201107&partnerID=8YFLogxK

U2 - 10.1155/2012/585018

DO - 10.1155/2012/585018

M3 - Article

C2 - 21941528

AN - SCOPUS:81555201107

VL - 2012

JO - Experimental Diabetes Research

JF - Experimental Diabetes Research

SN - 1687-5214

M1 - 585018

ER -